Synthesis and study of the antifungal activity of new mono- and disubstituted derivatives of a genetically engineered polyene antibiotic 28,29-didehydronystatin A1 (S44HP).
Mono- and disubstituted novel derivatives of the heptaene nystatin analog 28,29-didehydronystatin A(1) (S44HP, 1) were obtained by chemical modification of the exocyclic C-16 carboxyl and/or an amino group of mycosamine moiety. The strategy of preparation of mono- and double-modified polyene macrolides was based on the use of intermediate hydrophobic N-Fmoc (9-fluorenylmethoxycarbonyl) derivatives that facilitated the procedures of isolation and purification of new compounds. The antifungal activity of the new derivatives was first tested in vitro against yeasts and filamentous fungi, allowing the selection of the most active compounds that were subsequently tested for acute toxicity in mice. 2-(N,N-dimethylamino)ethylamide of 1 (2) and 2-(N,N-dimethylamino)ethylamide of N-fructopyranosyl-28,29-didehydronystatin A(1) (2a) were then selected for further evaluation in a mouse model of disseminated candidosis, and showed high efficacy while being considerably less toxic than amphotericin B (AmB). The compound with improved water solubility (2G, L-glutamic acid salt of 2) showed better chemotherapeutic activity than AmB in the mouse model of candidosis sepsis on a leucopenic background. Very low antifungal effect was seen after treatment with AmB, even if it was used in maximum tolerated dose (2 mg kg(-1)). Unlike AmB, compound 2G exhibited high activity in doses from 0.4 up to 4.0 mg kg(-1), despite leucopenic conditions.
Preobrazhenskaya
Maria N
MN
Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russian Federation. mnp@space.ru
Olsufyeva
Eugenia N
EN
Tevyashova
Anna N
AN
Printsevskaya
Svetlana S
SS
Solovieva
Svetlana E
SE
Reznikova
Marina I
MI
Trenin
Aleksey S
AS
Galatenko
Olga A
OA
Treshalin
Ivan D
ID
Pereverzeva
Eleonora R
ER
Mirchink
Elena P
EP
Zotchev
Sergey B
SB
D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects / Q000737:chemistry* / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D005818:Genetic Engineering; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D015394:Molecular Structure; D009761:Nystatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy* / Q000382:microbiology; D013329:Structure-Activity Relationship
D000935:Antifungal Agents; C511411:S44HP; D009761:Nystatin